JPJoaquín Alberto Padilla-Flores

Joaquín Alberto Padilla-Flores

*This is an algorithmically generated author record based on publicly available information.

Joaquín Alberto Padilla-Flores has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Rafael Moreno-Sánchez

    Affiliations Laboratorio de Control Metabólico, Carrera de Biología de la Facultad de Estudios Superiores Iztacala, UNAM, Los Reyes Ixtacala, Hab Los Reyes Ixtacala Barrio de los Árboles/Barrio de los Héroes, Tlalnepantla, México, Laboratory of Chemical Biology, National Institute of Chemical Physics and Biophysics, Tallinn, Estonia

    3 shared publications
  • Diana Xochiquetzal Robledo-Cadena

    Departamento de Bioquímica, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico

    2 shared publications
  • Jorge Luis Vargas-Navarro

    Laboratorio de Control Metabólico, Carrera de Biología de la Facultad de Estudios Superiores Iztacala, UNAM, Los Reyes Ixtacala, Hab Los Reyes Ixtacala Barrio de los Árboles/Barrio de los Héroes, Tlalnepantla, México

    2 shared publications
  • Sara Rodríguez-Enríquez

    Affiliation Laboratorio de Control Metabólico, Carrera de Médico Cirujano de la Facultad de Estudios Superiores Iztacala, UNAM, Los Reyes Ixtacala, Hab Los Reyes Ixtacala Barrio de los Árboles/Barrio de los Héroes, Tlalnepantla, México

    2 shared publications
  • Silvia Cecilia Pacheco-Velázquez

    Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, United States of America

    2 shared publications
  • Israel Pérez-Torres

    Departamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México

    1 shared publication

Latest Publications

  • Regulation of cancer redox metabolism by mutant p53

    by Jorge Luis Vargas-Navarro, Joaquín Alberto Padilla-Flores, Juan Carlos Granados-Rivas, Luis Antonio Aguilar-Torres, Sagiv Ali Gregori-Fattel, Rafael Moreno-Sánchez, Sara Rodríguez-Enríquez

  • Open Access

    Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms

    by Diana Xochiquetzal Robledo-Cadena, Silvia Cecilia Pacheco-Velázquez, Jorge Luis Vargas-Navarro, Joaquín Alberto Padilla-Flores, Rebeca López-Marure, Israel Pérez-Torres, Tuuli Kaambre, Rafael Moreno-Sánchez, Sara Rodríguez-Enríquez

    Objective: The synergistic inhibitory effect of celecoxib (CXB) and dimethyl-celecoxib (DMC) plus paclitaxel (PA) or cisplatin (CP) on human cervix HeLa and SiHa cells was assessed at multiple cellular levels in order to elucidate the biochemical mechanisms triggered by the synergistic drug combinations. Methods: The effect of CXB (5 μM)/CP (2 μM) or CXB (5 μM)/PA (15 μM) and DMC (15 μM)/CP (5 μM) or DMC (15 μM)/PA (20 μM) for 24 h was assayed on cancer cell proliferation, energy metabolism, mitophagy, ROS production, glycoprotein-P activity, DNA stability and apoptosis/necrosis. Results: Drug combinations synergistically decreased HeLa and SiHa cell proliferation (>75%) and arrested cellular cycle by decreasing S and G2/M phases as well as the Ki67 content (HeLa) by 7.5–30 times. Cell viability was preserved (>90%) and no apparent effects on non-cancer cell growth were observed. Mitochondrial and glycolytic protein contents (44–95%) and ΔΨm (45–50%) in HeLa cells and oxidative phosphorylation and glycolysis fluxes (70–90%) in HeLa and SiHa cells were severely decreased, which in turn promoted a drastic fall in the ATP supply (85–88%). High levels of mitophagy proteins in HeLa cells and active mitochondrial digestion in HeLa and SiHa cells was observed. Mitochondrial fission and microtubule proteins were also affected. Intracellular ROS content (2–2.3-fold) and ROS production was stimulated (2.3–4 times), whereas content and activity of glycoprotein-P (45–85%) were diminished. DNA fragmentation was not observed and apoptosis/necrosis was not detected suggesting that cell death could be mainly associated to mitophagy induction. Conclusions: CXB or DMC combination with canonical chemotherapy may be a promising chemotherapy strategy against cervical cancer growth, because it can selectively block multiple cell processes including inhibition of energy pathways and in consequence ATP-dependent processes such as cell proliferation, glycoprotein-P activity, ROS production and mitophagy, with no apparent effects on non-cancer cells.


  • Open Access

    Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs

    by Sara Rodríguez-Enríquez, Diana Xochiquetzal Robledo-Cadena, Silvia Cecilia Pacheco-Velázquez, Jorge Luis Vargas-Navarro, Joaquín Alberto Padilla-Flores, Tuuli Kaambre, Rafael Moreno-Sánchez

    Objective: Cytotoxicity of the antirheumatic drug auranofin (Aur) and the non-steroidal anti-inflammatory drug meclofenamic acid (MA) on several cancer cell lines and isolated mitochondria was examined to assess whether these drugs behave as oxidative phosphorylation inhibitors. Methods: The effect of Aur or MA for 24 h was assayed on metastatic cancer and non-cancer cell proliferation, energy metabolism, mitophagy and metastasis; as well as on oxygen consumption rates of cancer and non-cancer mitochondria. Results: Aur doses in the low micromolar range were required to decrease proliferation of metastatic HeLa and MDA-MB-231 cells, whereas one or two orders of magnitude higher levels were required to affect proliferation of non-cancer cells. MA doses required to affect cancer cell growth were one order of magnitude higher than those of Aur. At the same doses, Aur impaired oxidative phosphorylation in isolated mitochondria and intact cells through mitophagy induction, as well as glycolysis. Consequently, cell migration and invasiveness were severely affected. The combination of Aur with very low cisplatin concentrations promoted that the effects on cellular functions were potentiated. Conclusion: Aur surges as a highly promising anticancer drug, suggesting that efforts to establish this drug in the clinical treatment protocols are warranted and worthy to undertake.